Transferrin receptor 1 binds human parvovirus B19 VP1u to facilitate entry

This study identifies transferrin receptor 1 (TfR1/CD71) as the previously unknown cellular receptor (VP1uR) that binds to the VP1 unique region of human parvovirus B19 to facilitate viral entry into erythroid progenitor cells, a discovery supported by proximity labeling, antibody inhibition, and cryo-EM structural analysis.

The Gist

The Mystery of the "Red Blood Cell" Virus

Imagine Human Parvovirus B19 (let's call it "B19") as a tiny, mischievous burglar. This burglar has a very specific target: it only wants to break into red blood cell factories (erythroid progenitor cells) in your bone marrow. It ignores your liver, your skin, and your brain cells completely.

For a long time, scientists knew how the burglar got inside the factory (it used a special tool called VP1u to unlock the door), but they didn't know what the lock was. They knew there was a specific "keyhole" on the red blood cells that the virus's tool fit into, but they couldn't find the keyhole.

This paper solves that mystery. The scientists discovered that the keyhole is a protein called Transferrin Receptor 1 (TfR1).

Here is how they figured it out, step-by-step:

1. The "Sniffer Dog" Investigation (Proximity Labeling)

The scientists needed to find out what protein was standing right next to the virus's tool (VP1u) when it touched the cell.

• The Analogy: Imagine the virus's tool (VP1u) is a detective wearing a high-tech badge that sprays a glowing paint on anything it touches within a 5-foot radius.
• The Experiment: They attached this "paint-spraying" badge to the virus tool and let it touch the red blood cells. Then, they looked at what got painted.
• The Result: Almost everything got painted, but one specific protein, TfR1, was the only one that consistently got covered in the glowing paint every single time. It was the only thing standing close enough to the virus tool to be the lock.

2. The "Double-Check" (Microscopy)

They wanted to see if the virus tool and the TfR1 lock actually sat together on the surface of the cell.

• The Analogy: They took a high-resolution photo of the cell surface. They painted the virus tool Green and the TfR1 lock Red.
• The Result: Where the virus tool touched the cell, the Green and Red lights mixed to make Yellow (colocalization). They were holding hands!
• The Twist: When they used the whole virus (not just the tool), the whole virus didn't seem to hold hands with TfR1 immediately. This suggested the virus has a two-step entry process.

3. The "Brick Wall" Test (Antibody Blockade)

To prove TfR1 was essential, they tried to block it.

• The Analogy: Imagine TfR1 is a door handle. The scientists used a special antibody (OKT9) as a giant, sticky brick to cover the handle so no one could turn it.
• The Result:
  • When they blocked the handle, the virus's tool (VP1u) couldn't get in.
  • When they blocked the handle, the whole virus couldn't get inside the cell either.
  • Crucial Detail: The virus could still touch the door (attachment), but it couldn't open it and walk through (uptake). The brick didn't stop the virus from knocking; it just stopped it from entering.

4. The "Why Only Red Cells?" Puzzle

Here is the confusing part: TfR1 is found on almost all human cells, not just red blood cells. So why does the virus only infect red blood cells?

• The Analogy: If TfR1 is a standard door handle found on every house in the neighborhood, why can only the burglar enter the red blood cell house?
• The Discovery: The scientists tried to "scrape off" the sugar coatings (glycans) on the door handles of non-red blood cells, thinking maybe the virus needed a specific sugar flavor. It didn't work. The virus still couldn't get in.
• The Conclusion: The door handle (TfR1) is the same everywhere. The difference must be in the environment of the red blood cell factory. Something else in that specific factory helps the virus tool grab the handle, or perhaps the handle is positioned differently. The virus needs a specific "welcome mat" that only red blood cells have, even though the lock itself is everywhere.

5. The "X-Ray Vision" (Cryo-EM Structure)

Finally, the scientists used a super-powerful microscope (Cryo-EM) to take a 3D picture of the virus tool and the TfR1 lock stuck together.

• The Result: They built a molecular model showing exactly how the two fit together. It's like seeing the exact shape of a key fitting into a lock.
• The Fit: The virus tool (VP1u) has a specific shape (a three-helix bundle) that slots perfectly into a specific groove on the TfR1 handle. They even identified the exact atoms that touch each other, proving this is the real, physical connection.

The Big Picture: How the Virus Gets In

The paper proposes a clever two-step entry strategy for the virus:

1. Step 1 (The Knock): The whole virus lands on the cell and grabs onto some other surface factor (like a doormat). It doesn't need TfR1 for this.
2. Step 2 (The Unlock): Once it's there, the virus changes its shape, exposing its special tool (VP1u). This tool then grabs the TfR1 handle.
3. Step 3 (The Entry): Grabbing the TfR1 handle triggers the cell to swallow the virus, pulling it inside.

Why This Matters

• Solving a 20-year Mystery: Scientists have been looking for this specific "keyhole" for decades. Now we know it's TfR1.
• New Treatments: If we know the lock is TfR1, we can design drugs or antibodies (like the "sticky brick" they used) to block it. This could stop the virus from infecting red blood cells, which is vital for treating severe anemia or protecting unborn babies from the virus.
• Understanding Biology: It explains why this virus is so picky. It's not just about the lock; it's about the specific neighborhood (the red blood cell environment) that allows the lock to work.

In short: The virus uses a special tool (VP1u) to grab onto a universal handle (TfR1), but it can only do this successfully in the specific environment of red blood cell factories.

Technical Summary

1. Problem Statement

Human parvovirus B19 (B19V) exhibits an exceptionally narrow cellular tropism, infecting only erythroid progenitor cells (EPCs) in the bone marrow and fetal liver. While the viral capsid protein VP1 contains a unique N-terminal extension (VP1u) known to mediate this specific uptake, the molecular identity of the cellular receptor (termed VP1uR) that binds VP1u has remained elusive for decades. Previous research identified the glycosphingolipid globoside as a receptor, but it was found to be dispensable for initial viral uptake and essential only for post-entry endosomal escape. Furthermore, while the AXL receptor was recently proposed as an entry factor, it does not fully explain the strict erythroid restriction. The lack of a defined VP1u receptor hinders the understanding of B19V pathogenesis, transplacental transmission, and the development of targeted therapies.

2. Methodology

The authors employed a multi-faceted approach combining proteomics, cell biology, biochemistry, and structural biology to identify and characterize the receptor:

• Proximity Labeling (SPPLAT): To identify cell surface proteins in close proximity to VP1u, the researchers conjugated recombinant VP1u to horseradish peroxidase (HRP). They incubated this conjugate with UT7/Epo cells (a permissive erythroid cell line) at 4°C to allow surface binding without internalization. Upon adding biotinylated tyramide, HRP generated radicals that covalently labeled nearby proteins. These biotinylated proteins were affinity-purified and analyzed via quantitative mass spectrometry, filtering against the Cell Surface Protein Atlas (CSPA).
• Cell-Based Binding and Uptake Assays:
  • Colocalization: Confocal microscopy was used to visualize the co-localization of recombinant FLAG-tagged VP1u and intact B19V virions with Transferrin Receptor 1 (TfR1/CD71) at the cell surface.
  • Antibody Blockade: The murine monoclonal antibody OKT9, which targets the apical domain of human TfR1, was used to block receptor accessibility. Effects on VP1u binding, viral internalization, and productive infection (measured by NS1 mRNA levels) were assessed.
  • Cell Specificity: Binding assays were performed on non-erythroid cell lines (HeLa, HepG2, Jurkat) and erythroid-like cells (KU812Ep6) to determine if TfR1 expression or glycosylation patterns dictated binding.
  • Glycosylation Analysis: UT7/Epo cells were treated with various glycosidases (PNGase F, neuraminidase, etc.) to remove specific carbohydrate moieties from TfR1, followed by VP1u binding assays.
• Biochemical Binding Assays:
  • Mass Photometry: Used to confirm the formation of VP1u-TfR1 complexes in solution.
  • Bio-Layer Interferometry (BLI): Measured the binding kinetics and affinity ($K_D$) of monomeric and dimeric VP1u to immobilized TfR1.
• Cryo-Electron Microscopy (Cryo-EM):
  • The complex of monomeric VP1u and the recombinant human TfR1 ectodomain was vitrified and imaged.
  • Single-particle analysis was performed using symmetry expansion and focused classification to resolve the flexible VP1u density.
  • De novo model building (using ModelAngelo) and refinement were conducted to determine the atomic structure of the interface.

3. Key Contributions

• Identification of VP1uR: The study definitively identifies Transferrin Receptor 1 (TfR1/CD71) as the specific cellular receptor (VP1uR) required for B19V uptake.
• Structural Resolution: The authors solved the 2.4 Å resolution cryo-EM structure of the TfR1-VP1u complex, mapping the precise molecular interface.
• Mechanistic Clarification: The work distinguishes between the initial attachment of the virus (which is TfR1-independent) and the subsequent internalization step (which is strictly TfR1-dependent).
• Resolution of Tropism Paradox: The study addresses why B19V only infects erythroid cells despite TfR1 being ubiquitously expressed, ruling out glycosylation differences as the primary cause and suggesting a requirement for an erythroid-specific cellular context.

4. Key Results

• Proximity Labeling: Mass spectrometry identified TfR1 as the only consistently enriched cell surface protein proximal to VP1u across three independent experiments.
• Colocalization: Recombinant VP1u strongly colocalized with TfR1 at the plasma membrane of erythroid cells. In contrast, intact B19V virions did not colocalize with TfR1 at 4°C, suggesting the virus attaches via other factors first.
• Functional Blockade:
  • Pre-incubation with OKT9 completely abolished the binding and uptake of MS2-VP1u particles.
  • For intact B19V, OKT9 did not inhibit initial attachment at 4°C but completely blocked internalization at 37°C and subsequent productive infection (NS1 expression).
  • This confirms a sequential entry model: Attachment (TfR1-independent) $\rightarrow$ Conformational Change/Priming $\rightarrow$ VP1u Exposure $\rightarrow$ TfR1 Engagement $\rightarrow$ Internalization.
• Cell Specificity & Glycosylation:
  • Non-erythroid cells (HeLa, HepG2, Jurkat) express high levels of TfR1 but fail to bind VP1u.
  • Enzymatic removal of N-linked and O-linked glycans from TfR1 on erythroid cells did not reduce VP1u binding, ruling out glycosylation as the determinant of tropism.
• Biochemical Affinity: BLI and mass photometry confirmed direct binding between VP1u and TfR1. The interaction fits a heterogeneous ligand model with $K_D$ values in the low micromolar range (~3 µM). Dimerization of VP1u enhances functional uptake in cells but does not significantly alter intrinsic affinity in solution, suggesting avidity effects in the membrane environment.
• Structural Insights:
  • The cryo-EM structure reveals that two VP1u monomers bind to the two apical domains of the TfR1 dimer.
  • The binding interface involves the N-terminal loop, BC loop, and helices of the VP1u Receptor Binding Domain (RBD) interacting with the $\beta$II-1-$\beta$II-2 loop and $\beta$II-2 strand of the TfR1 apical domain.
  • Key contact residues (e.g., Phe15 of VP1u) were identified, and their locations align perfectly with previously known mutational data that abolished viral uptake.
  • The interface area is ~480 Ų, distinct from the broader interfaces used by other pathogens (e.g., canine parvovirus, human ferritin) on the same receptor.

5. Significance

This paper resolves a long-standing mystery in parvovirology by identifying TfR1 as the critical receptor for B19V entry. The findings have several major implications:

1. Mechanistic Framework: It establishes a clear, two-step entry mechanism for B19V, separating attachment from internalization. This explains how the virus can traverse barriers (like the respiratory epithelium or placenta) before engaging the specific erythroid uptake machinery.
2. Understanding Tropism: By demonstrating that TfR1 expression alone is insufficient for infection and that glycosylation is not the deciding factor, the study shifts the focus to erythroid-specific co-factors or the cellular microenvironment required for the VP1u-TfR1 interaction to be productive.
3. Therapeutic Targets: The high-resolution structure of the VP1u-TfR1 interface provides a blueprint for designing antivirals or neutralizing antibodies that specifically block the internalization step without affecting the essential physiological function of TfR1 (iron uptake).
4. Evolutionary Insight: The study highlights how a modular capsid extension (VP1u) can evolve to hijack a conserved cellular receptor (TfR1) to achieve strict tissue tropism, a mechanism distinct from the capsid-topology-based entry of other parvoviruses.